Zura Bio halted development of its experimental skin-disease drug after it missed the main goal in a mid-stage trial, sending shares down 75% in morning trading. The treatment failed to show a benefit over placebo in reducing abscesses and inflammatory skin nodules for patients with hidradenitis suppurativa after 16 weeks. Investors dumped the stock as the setback wiped out the primary catalyst for the company's dermatology pipeline.
Zura Bio Drug Fails Trial
Zura Bio shares dropped sharply after its experimental drug failed the main goal of a mid-stage study in treating a chronic skin disease. The company will discontinue development for this indication but plans to test the drug in other conditions.
Xurve View
Insights:
Xurve View




